Get to know our clinical trials
Clinical trial with CyPep-1 in combination with pembrolizumab to evaluate the efficacy and safety of CyPep-1 in patients with epidermoid carcinoma of the head and neck, melanoma or advanced or metastatic triple-negative breast cancer.
THE PURPOSE OF THIS STUDY IS TO EVALUATE AN INVESTIGATIONAL NEW DRUG, CYPEP-1, IN COMBINATION WITH PEMBROLIZUMAB, TO CONFIRM THE DOSE OF CYPEP-1 FOR THE TREATMENT OF ADVANCED OR METASTATIC ESCC, MELANOMA OR TNBC, AND TO TEST THE SAFETY OF CYPEP-1 IN THESE PATIENTS.
Technical Summary
- Code EudraCT: 2021-006804-34
- Protocol number: CYP003
- Promoter: Cytovation ASA
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.